Skip to search formSkip to main contentSkip to account menu

EPC2407

Known as: Microtubule Inhibitor EPC2407 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

crolibulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
New indole-based chalconoids as tubulin-targeting antiproliferative agents.
2016
2016
Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas
PurposeThe goal of the present study was to examine the safety and efficacy of the vascular disrupting agent (VDA) EPC2407… 
2015
2015
Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer
The high mortality rate associated with castration-resistant prostate cancer (CRPC) underscores the need for improving… 
Review
2013
Review
2013
Chromenes: potential new chemotherapeutic agents for cancer.
Cancer is a major devastating disease, and is a leading cause of death worldwide. Despite the progress in cancer treatment… 
Review
2009
Review
2009
Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular…
Many cancer cells are known to have defects in the apoptosis machinery. Therefore identification of compounds that can activate… 
2009
2009
Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent.
3569 Background: EPC2407 is a 4-aryl-chromene single isomer microtubulin inhibitor with vascular disrupting and apoptotic… 
2008
2008
Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity
2531 Background: EPC2407 is a 4-aryl-chromene single isomer microtubulin inhibitor which in preclinical models showed antitumor… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
2007
2007
EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition
2007
2007
A new microtubulin inhibitor with vascular disruption activity, EPC2407, enhances the antitumor activity of antiangiogenic or chemotherapeutic agents in xenograft tumor models
B4 EPC2407 is a small molecule new chemical entity vascular disruption agent (VDA) which also induces apoptosis. The biology… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)